Who are Beclometasone/Formoterol/Glycopyrrolate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Budesonide/Glycopyrronium/Formoterol Fumarate, BDP/FF/GB, CHF 5993 200/6/12.5 µg, Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium, FlF/VI + Tiotropium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/beclometasone-formoterol-glycopyrrolate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Beclometasone/Formoterol/Glycopyrrolate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beclometasone/Formoterol/Glycopyrrolate (Beclometasone/Formoterol/Glycopyrrolate) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA). Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Glucocorticoid receptor (beclometasone); beta-2 adrenergic receptor (formoterol); muscarinic M3 receptor (glycopyrrolate) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Beclometasone/Formoterol/Glycopyrrolate (Beclometasone/Formoterol/Glycopyrrolate) — Chiesi Farmaceutici S.p.A.. This triple-combination inhaler delivers a corticosteroid (beclometasone) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrrolate) to further relax airway smooth muscle.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Beclometasone/Formoterol/Glycopyrrolate TARGET	Beclometasone/Formoterol/Glycopyrrolate	Chiesi Farmaceutici S.p.A.	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor (beclometasone); beta-2 adrenergic receptor (formoterol); muscarinic M3 receptor (glycopyrrolate)
Budesonide/Glycopyrronium/Formoterol Fumarate	Budesonide/Glycopyrronium/Formoterol Fumarate	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol); muscarinic M3 receptor (glycopyrronium)
BDP/FF/GB	BDP/FF/GB	Chiesi Farmaceutici S.p.A.	phase 3	Triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
CHF 5993 200/6/12.5 µg	CHF 5993 200/6/12.5 µg	Chiesi Farmaceutici S.p.A.	phase 3	Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium	Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium	Chiesi Farmaceutici S.p.A.	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
FlF/VI + Tiotropium	FlF/VI + Tiotropium	Chiesi Farmaceutici S.p.A.	phase 3	Triple combination therapy: inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor (fluticasone furoate), beta-2 adrenergic receptor (vilanterol), muscarinic M3 receptor (tiotropium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) class)

Chiesi Farmaceutici S.p.A. · 2 drugs in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beclometasone/Formoterol/Glycopyrrolate — Competitive Intelligence Brief. https://druglandscape.com/ci/beclometasone-formoterol-glycopyrrolate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab